Scholars Central

Research articlePublished 24 Feb 2020

Fulminant Hepatitis Managed with Pentoxifylline

Authors: Jiménez-Luévano MA, Ramírez-Flores S, Sepúlveda-Castro R, Jiménez-Partida AE, Jiménez-Partida MÁ, Ruiz-Mercado H, Cortés-Aguilar Y, Bravo-Cuellar A, Hernández-Flores G

Journal of Clinical & Experimental Pharmacology

Volume 10 · Issue 1 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Fulminant hepatitis is a severe clinical entity that has a prevalence of 10/1,000,000, and its mortality can reach 80% of registered cases. Its etiology is multifactorial and does not respect gender, age, or socioeconomic or cultural levels. Transcription factor NF-κB, oxidative stress, proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 and growth factors play a fundamental role in this pathology. Treatment-of-choice is liver transplantation; however, the latter is far from being the ideal solution due to its accessibility and cost. Thus, we use the Pentoxifylline inhibitor of NF-κB and inflammatory and oxidative processes. Objective: To assess the response of patients with fulminant hepatitis using pentoxifylline. Methods: The four pediatric cases, diagnosed and classified with fulminant hepatitis, presenting all indicators of poor prognosis according to the criteria of British Kings College. These patients received treatment with Pentoxifylline 200 mg every 12 h i.v. All patients received the following support treatment: fresh plasma; vitamin K; anti-ammonium measures; anti-cerebral edema (Mannitol); antimicrobials; ventilatory support; parenteral solutions, as well as parenteral and enteral nutrition (when they tolerated administration via the oral route). Results: Presenting a favourable response to the on-average 2 weeks of treatment initiation, in relation to neurological, cognitive, and hemodynamic damage, with clinical and laboratory improvement, evaluating the patients discharged without presenting complications between days 8-10 days after leaving the Intensive Care Unit (ICU). Conclusion: The results confirm previous observations and are encouraging for multicenter and randomized studies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical & Experimental Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pharmacology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jiménez-Luévano MA”
  • BylineArticles whose byline prints “Ramírez-Flores S”
  • BylineArticles whose byline prints “Sepúlveda-Castro R”
  • BylineArticles whose byline prints “Jiménez-Partida AE”
  • BylineArticles whose byline prints “Jiménez-Partida MÁ”
  • BylineArticles whose byline prints “Ruiz-Mercado H”
  • BylineArticles whose byline prints “Cortés-Aguilar Y”
  • BylineArticles whose byline prints “Bravo-Cuellar A”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels